Safety and efficacy of the PrePex device in HIV-positive men: A single-arm study in Zimbabwe

Mufuta Tshimanga, Batsirai Makunike-Chikwinya, Tonderayi Mangwiro, Patricia Tapiwa Gundidza, Pesanai Chatikobo, Vernon Murenje, Amy Herman-Roloff, Peter H. Kilmarx, Marrianne Holee, Gerald Gwinji, Owen Mugurungi, Munyaradzi Murwira, Sinokuthemba Xaba, Scott Barnhart, Caryl Feldacker

1 Zambabwe Community Health Intervention Project (ZICHIRE), Harare, Zimbabwe, 2 International Training and Education Center for Health (I-TECH), Harare, Zimbabwe, 3 Department of Health Sciences, University of Zimbabwe, Harare, Zimbabwe, 4 U.S. Centers for Disease Control and Prevention, Harare, Zimbabwe, 5 International Training and Education Center for Health (I-TECH), Seattle, Washington, United States of America, 6 Ministry of Health and Child Care, Harare, Zimbabwe, 7 Zimbabwe National Family Planning Council (ZNFPC), Harare, Zimbabwe, 8 Department of Medicine, University of Washington, Seattle, Washington, United States of America, 9 Department of Global Health, University of Washington, Seattle, Washington, United States of America

* cfeld@uw.edu

Abstract

Male circumcision (MC) for sexually active, HIV-negative men reduces HIV transmission and averts HIV infections. Excluding HIV-positive men from MC decreases access to additional health and hygiene benefits. In settings where HIV-testing is, or is perceived to be, required for MC, testing may reduce MC uptake. Reducing promotion of HIV testing within MC settings and promoting device-based MC may speed MC scale-up. To assess safety and efficacy of PrePex MC device among HIV-positive men, we conducted a one-arm, open-label, prospective study in otherwise healthy HIV-positive men in Zimbabwe.

Methods

We aimed to determine if the adverse event (AE) rate was non-inferior to an AE rate of 2%, a rate considered the global standard of MC safety. Study procedures, AE definitions, and study staff were unchanged from previous PrePex Zimbabwe trials. After PrePex placement and removal, weekly visits assessed wound healing. Men returned on Day 90. Safety was defined as occurrence of moderate and serious clinical AEs. Efficacy was defined as ability to reach the endpoint of complete circumcision.

Results

Among 400 healthy, HIV-positive, consenting adults, median age was 40 years (IQR: 34, 46); 79.5% in WHO stage 2; median CD4 was 336.5c/μl (IQR: 232, 459); 337 (85%) on anti-retroviral therapy. Among 385 (96%) observed completely healed, median days to complete healing was 42 (IQR: 35–49). There was no association between time to healing and CD4 (p = 0.66). Four study-related severe AEs and no moderate AEs were reported: severe/moderate AE rate of 1.0% (95% CI: 0.27% to 2.5). This was non-inferior to 2% AEs.
Male circumcision among healthy, HIV-positive men using PrePex is safe and effective. Reducing the barrier of HIV testing while improving counseling for safer sex practices among all MC clients could increase MC uptake and avert more HIV infections.

Background

Male circumcision (MC) reduces the risk of female-to-male HIV-1 transmission by 60% [1–3]; millions of new HIV infections, and subsequent deaths, could be averted if MC coverage is reached [4]. Surgical MC has proven safe in both controlled and field settings [1–3, 5–11]. From 2008–2015, nearly 14.5 million voluntary medical male circumcision (VMMC) procedures were performed across 14 African countries [12], shy of the 20 target million needed [13] to avert 3.4 million HIV infections and save $16.5 billion in HIV-related care through 2025 [14].

Non-surgical MC devices, such as PrePex, have the potential to accelerate VMMC program scale up. In pilot studies and controlled trials among HIV-negative men in sub-Saharan Africa, PrePex has proven safe and acceptable with moderate and severe adverse event (AE) rates (most commonly from device displacement, swelling, pain) from 0–5.9% [6, 9, 15–20]. Globally, few reported AEs from any method of MC, including PrePex, resulted in permanent impairment or death. PrePex is considered faster, simpler to implement, and, with some exception [21], may be more cost effective when compared to surgical MC [22–24]. PrePex may be safely applied by less highly trained cadres of nurses and clinicians [19, 25, 26]. In some contexts, devices appear more acceptable than surgical MC as they do not cause prolonged pain [6] nor interrupt activities of daily living for most clients [18]. For these reasons, PrePex offers an important tool to accelerate VMMC programs to meet targets especially in men over age 18 years.

VMMC is almost-exclusively promoted for sexually active, HIV-negative men as part of comprehensive HIV prevention [13]. To reach HIV-negative men, VMMC is commonly accompanied by HIV testing. HIV-related stigma, however, may reduce acceptance of HIV testing [27] and, therefore, VMMC uptake in sub-Saharan Africa [28–30]. Recent modeling shows that inclusion of all men regardless of HIV status may significantly increase the effectiveness of VMMC scale up by reaching more at-risk males, potentially improving the pace of HIV infection prevention in countries most in need [31]. Moreover, there are additional benefits to adult male circumcision including improved hygiene [32], reduction in penile cancers [33, 34], and decreases in some sexually transmitted diseases [35, 36], advantages of which some may apply to HIV-positive men [37]. Although HIV-positive men have largely been ignored in both surgical and PrePex MC scale-up efforts [38], access to VMMC is desirable for all men regardless of HIV status.

Surgical VMMC appears safe in otherwise healthy, HIV-positive men [8, 39–41]. Yet, research on the safety of use of MC devices such as PrePex in HIV-positive men is very limited. This lack of evidence is most acute where rapid expansion of male circumcision programs is most urgent, including Zimbabwe. Although HIV testing is not a precondition to...
being circumcised in Zimbabwe, it is strongly recommended as part of the minimum package of essential HIV prevention services [42, 43]. Virtually all men in Zimbabwe are HIV tested prior to circumcision [44, 45]. Although HIV testing is an important component of combination HIV prevention, qualitative research in Zimbabwe found that the presumption of HIV testing prior to VMMC presents a formidable barrier to VMMC among some men due to fear of, or reluctance to, HIV test. [46, 47]. Quantitative studies, also from Zimbabwe, further support the strength of this persistence barrier, finding that between 36% [48] and 50% [49] of men noted that HIV testing before the procedure was a reason to avoid VMMC. If, however, surgical and device-based VMMC is safe for HIV-positive men, then the need for HIV testing before VMMC is reduced. Revised messaging to promote the availability of, but not requirement for, HIV testing within VMMC settings could diminish the perceived mandate for HIV testing, thereby increasing VMMC uptake among all men. As Zimbabwe’s progress towards national VMMC goals is slower than expected [50], aiding demand for VMMC could speed efforts to avert new HIV infections. Increased risk reduction counseling on the importance of abstinence or condom use during the healing period for all men regardless of HIV status would be beneficial in conjunction with lessened emphasis on HIV testing before VMMC.

In order to assess the safety and efficacy of the PrePex device in HIV-positive men, we conducted a one-arm, open-label, prospective study in otherwise healthy HIV-positive adult men in Zimbabwe. If PrePex proves safe for use among HIV-positive men, PrePex could be promoted to all men regardless of HIV status, including those with unknown status. Therefore, results from this study may inform policy and clinical practice pertaining to HIV testing among men seeking circumcision (S1 Table).

Methods

Study design and sample size

This study aimed to determine if the AE rate among the study population, composed of HIV-positive men who receive PrePex MC, was non-inferior to that of the historical proportion of men who experience an AE with surgical MC of 2% [1–3]. The historical AE rate of 2% was selected as it is generally consistent with the AE rates of previous MC randomized control trials [1–3] and because an AE rate of \( \leq 2\% \) is regarded both as an acceptable global standard of VMMC safety and the adopted standard of care for Zimbabwe [51–53]. The non-inferiority margin, based on statistical and clinical considerations, is the maximum difference between the rate of AEs among HIV-positive men using PrePex and historical controls where we would conclude that PrePex among HIV-positive men is not inferior to routine care. That margin was set at 2%, determining that a 4% AE rate would be non-inferior. Including a possible 20% lost to follow up, 400 participants per arm provides 80% power at an alpha of 2.5% to detect if AEs exceeded the non-inferiority margin of 2%. The study protocol is available in S1 Text. The trial is registered at ClinicalTrials.gov (STUDY00000126).

Study team

Procedures were conducted by two surgeons (National PrePex Master trainers) and three nurses who had undergone PrePex training in 2011, were involved in previous PrePex studies in 2011 and 2012, and had additional training for the current study. The initial 50 PrePex circumcisions were conducted by the surgeons; the remaining 350 circumcisions were conducted by the nurse providers.
Study site and recruitment

The study was implemented in Chitungwiza, a large urban area outside of Harare by the same team comprised of the same cadres of staff that carried out previous PrePex studies in Zimbabwe, mentioned above. For staff, brief training included updates on the minimum package of VMMC services, the potential for increased risk of HIV transmission to providers and partners, and the need to maintain expected standards of strict infection control measures. Participant recruitment from HIV treatment clinics sites was conducted from October 2015 to May 2016; follow-up lasted 90 days. Nurses at these clinics discussed the study about MC for HIV-positive men during routine education sessions for all HIV-positive men; any interested men traveled independently or with study-provided transport to Seke South Clinic for further assessment. This process also reduced possible stigma of participants or the association of the VMMC clinic with only HIV-positive men.

At Seke South, any males aged 18 and above interested in circumcision who accepted to be HIV tested, and who tested HIV-positive, could participate in the study. This included men who initially heard about the study at HIV treatment clinics or who independently came for VMMC at Seke South. Further inclusion criteria included: confirmed HIV-positive status; WHO HIV clinical stage 1 or 2; agreed to be circumcised using PrePex; agreed to return to the health care facility for study follow-up visits; and agreement to anonymous photographs. Exclusion criteria included: known bleeding or coagulation abnormality; uncontrolled diabetes; active genital infection; or anatomic abnormality. Potential participants who did not meet the inclusion criteria were offered surgical circumcision.

Study procedures

All participants who consented to study participation received the minimum package of VMMC services that included information about the risks and benefits of the MC procedure, HIV testing, and management of sexually transmitted infections (if found during VMMC eligibility examination) before the procedure. Participants were also reminded about the added risk of HIV infection to their partners if they resumed sex before complete healing and received counselling about the need to adopt and maintain safer sexual practices, complemented by condom promotion during all post-procedure follow-up visits. CD4 data from participants were collected using a small finger prick to obtain blood sample and analyzed using PIMA Point of care CD4 machine.

After placement at Day 0 and removal at Day 7, additional weekly visits for clinical review were scheduled for all participants until the wound was assessed as healed. Participants were also asked weekly about resumption of sexual activity until they were assessed as healed. If a participant failed to attend the scheduled weekly visit, up to three contact attempts were made by phone and SMS. For a missed Day 7 device removal visit, the study nurse also attempted at least two home visits. In addition, participants were instructed to return to the clinic for an unscheduled visit if they experienced any AEs or complications with the device. All men were asked to return for a Day 90 visit for a final physical exam. All participants were reimbursed US $6 for travel for each study visit.

Data management

Definitions

Safety was defined as the occurrence of any moderate and serious clinical AEs as defined in previous clinical trials in Zimbabwe [54] including the following AE types, among others: site bleeding, penis-diffused hematoma, penis-diffused edema, and incision site infection
If two AEs occurred in the same individual, the more severe AE was considered in the safety analysis. Expected, mild side effects such as minor localized edema, oozing, and clear exudates are not included in the primary safety endpoint. Efficacy was defined as fully healed without surgical intervention at the end of the study. Time to complete wound healing was defined as the number of days from the date of device placement (not from the date of intended or actual device removal) to the first date when complete wound epithelialization was observed.

Analysis

Data were analyzed using STATA 12.0. Binomial probability tests evaluated equivalence of proportions; Clopper-Pearson exact confidence intervals were calculated.

Ethical conduct of the study

Institutional review boards approved the study at the Medical Research Council of Zimbabwe (MRCZ); the University of Washington; and the U.S. Centers for Disease Control and Prevention (CDC). Participants voluntarily provided written informed consent. A Data Safety Monitoring Board of Zimbabwean medical experts met four times over the course of the study to provide oversight in protocol adherence, patient safety, and data quality and in all phases of the trial. This manuscript was reviewed for clearance by CDC.

Results

Recruitment, screening, eligibility and demographic characteristics

A total of 1094 clients were recruited (Fig 1); 309 were under age 18. Of adult men, 28 declined (2.6%), showing that most HIV-positive men interested in VMMC as part of the study found PrePex to be acceptable. Of 757 adults screened, 400 were eligible. Table 1 also details ineligibility among those who met overall inclusion criteria.

Of the 400 eligible participants, the median age of participants enrolled in the study was 40 years (range: 18–70) (Table 2). The majority of participants were in WHO stage 2 (79.5%). Median CD4 was 336.5cell/μl, with a range of 8 to 1050 cell/μl. Almost 85% of men (337/400) were on anti-retroviral therapy (ARVs) at the time of MC. Most (75.2%) participants came from Chitungwiza.

Device removal

The vast majority (394 (98.5%)) of devices were successfully removed on-site on Day 7 following placement. For the six other participants, one removed their device within hours of placement and no further intervention was required; one participant reported removal on day 7 at another site; 4 others were considered AEs and described below.

Adherence to study visits

Participants were expected to attend all scheduled visits according to the study schedule until complete healing was assessed. As noted previously, 98.5% of men attended the Day 7 removal visit; 96.5% attended the 14-day visit. Thereafter, weekly visit adherence through Day 42, the final day of assessment for routine PrePex VMMC, was 93% or greater at each time point. Visit adherence among those not assessed as healed dropped to 88.3, 77.4, and 47.6 for Days 49, 56, and 63, respectively. All participants were requested to return for the Day 90 study closeout visit: final study visit attendance was 94.2%. All men who did not report to the final
Fig 1. CONSORT flow diagram.

https://doi.org/10.1371/journal.pone.0189146.g001
visit were contacted by phone and reported being healed. Reasons for missed reviews included being out of town, work commitments, and being outside the country.

### Time to complete healing

PrePex proved efficacious: 385 (96%) were observed as being fully healed without surgical intervention. Time to complete healing for those 385 participants who attended review visits at the scheduled time and presented by study visit date (Table 3). Assessment of complete healing was established if the scar was soft and pliable upon pinching and a stretching test showed no breach. Ten participants missed their review visits before complete healing could be observed but reported full healing via study follow-up call. As described above, four men were surgically circumcised after device displacement and one man was not circumcised. Median days to complete healing was 42 days (IQR: 35–49; range 28–70); mean time to healing was 42.3 days. Eighty-eight percent of men were fully healed by Day 49. Only four men (1.0%) reported having sex before they were observed as fully healed; three of the four were on ARVs. There was no significant association between time to complete healing and CD4 (p = 0.66) (Table 3) nor time to complete healing and ARV status (p = 0.17).

### Adverse events

There were four cases of expected side effects: all four were cases of localized edema managed by penile elevation. No moderate AEs were reported.
Table 2. Participant demographics (N = 400).

| Characteristic (Mean; *IQR) | Frequency | Proportion (%) |
|-----------------------------|-----------|----------------|
| Age (40.3; 33.5–46.0)       |           |                |
| <25                         | 18        | 4.5            |
| 25–34                       | 87        | 21.8           |
| 35–44                       | 173       | 43.3           |
| 45+                         | 122       | 30.5           |
| CD4 (352.1; 232–459)        |           |                |
| 0–199 c/μl                 | 76        | 19.0           |
| 200–499 c/μl               | 249       | 62.3           |
| ≥500 c/μl                  | 75        | 18.7           |
| WHO clinical stage          |           |                |
| Stage 1                     | 82        | 20.5           |
| Stage 2                     | 318       | 79.5           |
| ARV regimen                 |           |                |
| 1st line                    | 322       | 80.5           |
| 2nd line                    | 15        | 3.7            |
| None                        | 63        | 15.8           |
| Marital Status              |           |                |
| Married                     | 306       | 76.5           |
| Single                      | 44        | 11.0           |
| Separated / Divorced        | 29        | 7.3            |
| Widowed                     | 21        | 5.3            |
| Type of employment          |           |                |
| Informal                    | 210       | 52.5           |
| Formal                      | 118       | 29.5           |
| Unemployed                  | 65        | 16.3           |
| Student                     | 7         | 1.8            |
| Residence                   |           |                |
| Chitungwiza                 | 301       | 75.2           |
| Other                       | 99        | 24.8           |

*IQR = Interquartile range

https://doi.org/10.1371/journal.pone.0189146.t002

Table 3. Percent of men healed at each visit, by CD4 (N = 385).

| Visit date* | CD4 | Row Total | Row % | Cumulative % |
|-------------|-----|-----------|-------|--------------|
|             | 0–199 | 200–499 | ≥500 |               |
| <Day 28     | 7 (10.0) | 12 (5.0) | 6 (8.2) | 25 | 6.5 | 6.5 |
| Days 29–35  | 20 (28.6) | 65 (26.9) | 17 (23.3) | 102 | 26.5 | 33.0 |
| Days 36–42  | 19 (27.1) | 74 (30.6) | 26 (35.6) | 119 | 30.9 | 63.9 |
| Days 43–49  | 18 (25.7) | 59 (24.4) | 14 (19.2) | 91 | 23.6 | 87.5 |
| Days 50–56  | 3 (4.3) | 20 (8.3) | 9 (12.3) | 32 | 8.3 | 95.8 |
| Days 57–63  | 3 (4.3) | 11 (4.5) | 1 (1.4) | 15 | 3.9 | 99.7 |
| >Day 63     | 0 | 1 (0.4) | 0 | 1 | 0.3 | 100.0 |
| Total       | 70 (18.2%) | 242 (62.9%) | 73 (19.0) | 385 |

*Days post placement

https://doi.org/10.1371/journal.pone.0189146.t003
A total of four study-related severe AEs were reported resulting in a severe AE rate of 1.0% (95% CI: 0.27% to 2.5%). The study’s AE rate of 1% is less than or equal to the 4% upper bound for safety as determined for non-inferiority as defined in this study (p = 0.0003).

AE details are provided in S3 Text. Four device displacements, when the PrePex device was intentionally (1 case) or accidentally (3 cases) dislodged during the 7-day placement period, were reported: one on day 1; two on day 3; and one on day 5. All device displacements were resolved with surgical circumcision. These are considered severe because a surgical MC procedure is required as part of clinical management. Due to their HIV-positive status, and at the discretion of the treating clinician, three of these men were given oral antibiotics after surgical MC as a precaution against infection. All four men healed completely. Additionally, two non-study-related severe AEs were reported and not included in the study-related AE rate. One urethral stricture detected on day 37 was determined to be a pre-existing condition the client first noted, but did not initially report, September 2015, and resolved after bladder catheterization. One study participant death was reported due to car accident on day 35, unrelated to the study. There were no cases of partial or complete glans removal, penile loss, or study-related deaths.

### AEs among Zimbabwe historical controls

The study qualitatively compare the AE results to three previous PrePex device trials in Zimbabwe led by the same study team (Table 4). In Phase 1, the initial safety trial in Zimbabwe conducted in October-November, 2011, 53 HIV-negative adults underwent PrePex; 3 mild AEs were found [57]. Phase 2, November, 2011-January, 2012, compared PrePex and forceps guided VMMC among HIV-negative adults [22] finding no AEs among 80 forceps guided clients and 2 mild AEs (1.3%) among 158 PrePex clients (95% CI: 0.003–4.53%). In Phase 3, 603 adult men had PrePex placed by registered general nurses; 4 men (0.7%) had moderate AEs (1 urethral cut at removal; 1 difficult removal requiring sutures; 1 wound gaping, and 1 device displacement) that resolved within the expected healing period [58]. Lastly, recent VMMC program data on PrePex and surgical clients in Zimbabwe from October 2014 to September 2015, found 0.3% of surgical and 1.2% of PrePex clients experienced a moderate or severe AE [59], with PrePex AEs commonly due to device displacements (70%), infection (20%), and pain (12%).

### Discussion

This study demonstrated that PrePex is safe for healthy, HIV-positive men in WHO stage 1 or 2. With a moderate/severe AE rate of 1.0%, the risk of AEs in this study is not different from the AE rate from previous PrePex trials and routine program delivery among HIV-negative men within Zimbabwe [22, 57–60] nor does it differ from rates found in other previous PrePex
or devices studies [61] among HIV-negative men in the region. Additionally, there were no moderate AEs reported and the severe AEs noted in the study were device displacements which resulted in correction with surgical MC, the MC method they would have in the absence of PrePex. Although the study’s AE rate is higher than the all-method, national VMMC program AE rate of 0.35% [53], it is non inferior in terms of safety as compared to the accepted AE risk of ≤2%. With adherence to follow-up visit at Day 14 of almost 97%, it is unlikely that additional severe or moderate AEs were missed since most AEs from surgical MC are also expected before Day 14 [5, 62], and over 95% of all AEs within routine VMMC service delivery are reported by Day 14 [63]. Previously, only known HIV-negative men were candidates for PrePex. The findings of this study support extension of PrePex for healthy HIV-infected men as well as healthy men who refuse HIV testing and, therefore, have unknown HIV status. Counseling for, and access to, HIV testing should remain a core component of combination HIV prevention [64].

Prior to this study, there was no published data on time to healing among HIV-positive men using PrePex. This study demonstrated that PrePex is efficacious for HIV-positive men. Of the 400 men, 385 were observed as fully healed using the PrePex method (96%); 10 more men reported complete healing by phone, bringing efficacy to 99% (395/400). The mean time for healing among the 385 men was 42 days after placement, similar to healing time from PrePex prequalification (44.1 days) [65] and within the healing range of PrePex studies among HIV-negative men with means of 32.3 [17] and 48 days post placement [9]. As compared to previous studies conducted by the same study team among HIV-negative men, median time to complete healing was the same at 42 days post placement [57, 58, 60]. However, the proportion of men fully healed by Day 42 in this study of 64% is lower than the 79.2% [57], 87% [22], and 80.2% [58] found among HIV-negative men, suggesting a slower pace of healing for HIV-positive men. During this extended healing period, these men may be shedding virus and, potentially, increasing HIV transmissions. This possibility must be effectively addressed through improved counseling on abstinence until fully healed especially for HIV-infected or HIV-unknown men.

Although healing may be slower among HIV-positive men who have PrePex VMMC, CD4 count was not related to time to complete wound healing. In accordance with Zimbabwe policy, the current VMMC program Client Intake Form ascertains HIV status and includes both CD4 and WHO stage as part of the medical screening and physical examination. Only WHO staging is required before VMMC: those in Stages I and II may be circumcised while men in Stages 3 and 4 require care and treatment before VMMC. CD4 count is not mandatory but can be used if available. These results suggest WHO clinical staging may be a better determinant of a client’s eligibility for safe circumcision over CD4 and would address the lack of CD4 services in low resource settings where both HIV burden and demand for HIV prevention services, like VMMC, is high. If the results of this study are leveraged to reduce the barrier of HIV testing and, therefore, increase VMMC uptake among HIV-positive men or men with unknown HIV status, it is possible that HIV-positive, asymptomatic, WHO Stage 3 men could get circumcised. As all men receive a thorough exam and medical history as part of VMMC eligibility, and all VMMC programs assess AEs as part of routine follow-up, these standard practices appear sufficient to maintain client safety.

These results on time to healing among HIV-positive men after PrePex MC and lack of relationship between CD4 and healing time echoes the results of surgical MC studies. A study in Kenya using the forceps-guided method among adult men found no statistically significant difference in mean time to complete healing: 33 days for HIV-positive vs. 31 days for HIV-negative [41], but, unlike this study, did find a difference by CD4 status with mean time to complete healing of 37.1 days among men with CD4<350 as compared 31.1 days among those
with a CD4 count greater than 350 (p = 0.04). In Uganda, a study using the surgical sleeve method found that more than 90% of wounds healed by 6 weeks post-MC; however, HIV-negative men healed slightly faster: complete wound healing was certified in 73% of HIV-positive men and 83.2% of HIV-negative men (p<0.001) at 30 days post-MC [39]. Another study in Uganda using surgical dorsal slit method among men ages 12 and older found no significant difference in time to healing by HIV or CD4 status [66]. In summary, wound healing for those who are HIV-positive, including those with CD4 <350, may be slightly longer than for those who are HIV-negative, suggesting the need for increased HIV prevention counseling for men on the important of abstinence or condom use until complete healing is confirmed.

Although there is some hesitation to circumcise HIV-positive men due to a perceived higher risk of HIV transmission to partners during the healing process, in this study, most were on ARVs at the time of MC and only four men, three of whom were on ARVs, reported having sex the week before they were fully healed. It appears that most men abstained from sex until complete healing as instructed, reducing risk to partners. Moreover, the Zimbabwe Population-Based HIV Impact Assessment (Zimphia) 2015–2016 found that of men who knew their HIV status, 86.0% reported taking ARVs, and 84.1% of men on ARVs reported being virally suppressed [67], potentially reducing the risk of transmission during the healing process. Men may underreport sexual activity; however the overall risks to female partners, especially during the healing process, are difficult to quantify and remain unclear [68–70]. Although more research is needed, the risk of potential HIV transmission to female partners may not be a strong enough argument against circumcising HIV-positive men or those with unknown status within the VMMC program. What is clear is that men who undergo PrePex MC, especially those who are HIV-positive, must be well counselled to abstain from sex or to use a condom for both HIV transmission prevention and wound protection for at least seven weeks post device placement or until fully healed [65].

It is critical to note that the benefits of VMMC extend beyond HIV, benefits that may extend to HIV-positive men. VMMC brings hygienic benefits, an opinion shared by both men and women [32] and protects males from cancers of the penis, urinary tract infections and ulcerative sexually transmitted diseases [71–73]. VMMC also improves penile hygiene and reduces the risk of balanitis, which also affect HIV-positive men. VMMC reduces the prevalence and incidence of human papilloma virus infections in female partners [37, 69, 74, 75], a benefit that may also reach partners of HIV-positive men [37], decreasing the risk of cervical cancer among these women.

This study has several limitations. First, this study compared the AE rate to historical controls in the same facility using the same providers and to the global acceptable standard of AEs of ≤2%; there is no within-study comparison group for this study. However, because we looked at both the previous studies’ AE rates using the same study team and also looked at AE rates among HIV-negative men in a large, routine VMMC program in Zimbabwe, we believe the results of this one-arm study overcome this weakness. Moreover, the AE definitions and severity categorizations used in this study are less conservative than the revised AE guidelines used in the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) programs as of 2013, potentially leading to reductions in diagnosis or reporting of AE severity in this study. However, using the revised AE guidelines to review the data[76] and applying the most conservative definitions, three additional moderate AEs (infections) could be considered as three of the four device-related AEs cases were given antibiotics as potential infection could not be confidently ruled out, leading to an AE rate of 1.8% (7/400). This would not alter the study conclusions. Men in this study were recruited from HIV treatment clinics, increasing the likelihood that they were on ARVs. Lastly, this study did not collect variables related to HIV transmission (viral load, viral shedding, condom use) nor enroll female partners for longitudinal follow-up.
Despite these limitations, we believe results support the safe, effective use of PrePex among HIV-infected men.

**Conclusion**

Male circumcision among healthy HIV-positive men using the PrePex device is safe. The risk of adverse events is not different than the ≤2% rate used as a standard of quality care for MC practice. The only AEs found in this study were device displacements. Also, this study included men with low CD4; yet, CD4 did not appear a factor in the occurrence of study-related AEs. Therefore, it appears that WHO clinical staging is sufficient for VMMC inclusion criteria for HIV-positive men, reducing the need for CD4 testing before VMMC. We strongly support both HIV testing and VMMC as critical components of comprehensive HIV prevention. However, as PrePex appears safe for all men regardless of HIV status, it is important to weigh promotion of HIV testing against the benefits of VMMC for men who might otherwise shy away from MC services fearing HIV test results. Therefore, we recommend that HIV testing be advertised to potential VMMC clients as, “recommended, not mandatory”. In concert with continued promotion of safer sex practices in line with VMMC guidelines and increased risk reduction counseling for abstinence or condom use until completely healed for all men, we expect that service provision could be made more efficient and VMMC uptake increase as a result of this suggested policy change, averting additional HIV infections in the region.

**Supporting information**

S1 Table. Trend checklist.  
(DOCX)

S1 Text. Study protocol.  
(DOCX)

S2 Text. Zimbabwe AE definitions.  
(DOCX)

S3 Text. Details on study-related AEs.  
(DOCX)

**Acknowledgments**

The authors wish to thank the Zimbabwe Ministry of Health and Child Care, the VMMC teams from Chitungwiza district, and the study participants for their dedication to this PrePex study.

**Disclaimer**

The findings and conclusions of this report are those of the authors and do not necessarily represent the official position of the funding agencies. The authors declare that they have no competing interests.

**Author Contributions**

**Conceptualization:** Mufuta Tshimanga, Amy Herman-Roloff, Peter H. Kilmarx, Gerald Gwinji, Owen Mugurungi, Munyaradzi Murwira, Sinokuthemba Xaba, Scott Barnhart, Caryl Feldacker.
Data curation: Patricia Tapiwa Gundidza, Caryl Feldacker.

Formal analysis: Patricia Tapiwa Gundidza, Caryl Feldacker.

Funding acquisition: Mufuta Tshimanga, Batsirai Makunike-Chikwinya, Amy Herman-Roloff, Peter H. Kilmarx, Scott Barnhart.

Investigation: Mufuta Tshimanga, Caryl Feldacker.

Project administration: Mufuta Tshimanga, Batsirai Makunike-Chikwinya, Pesanai Chakobo, Vernon Murenje, Marianne Holec, Sinokuthemba Xaba.

Supervision: Mufuta Tshimanga, Batsirai Makunike-Chikwinya, Tonderayi Mangwiro.

Validation: Patricia Tapiwa Gundidza, Caryl Feldacker.

Writing – original draft: Peter H. Kilmarx, Caryl Feldacker.

Writing – review & editing: Mufuta Tshimanga, Batsirai Makunike-Chikwinya, Patricia Tapiwa Gundidza, Amy Herman-Roloff, Marianne Holec, Scott Barnhart.

References

1. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. The Lancet. 2007; 369(9562):657–66. Epub 2007/02/27. https://doi.org/10.1016/S0140-6736(07)60312-2 PMID: 17321310.

2. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007; 369(9562):643–56. Epub 2007/02/27. https://doi.org/10.1016/S0140-6736(07)60312-2 PMID: 17321310.

3. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Medicine. 2005; 2(11):e298. https://doi.org/10.1371/journal.pmed.0020298 PMID: 16231970.

4. Williams BG, Lloyd-Smith JO, Gouws E, Hankins C, Getz WM, Hargrove J, et al. The potential impact of male circumcision on HIV in Sub-Saharan Africa. PLoS medicine. 2006; 3(7):e262. https://doi.org/10.1371/journal.pmed.0030262 PMID: 16822094.

5. Reed J, Grund J, Liu Y, Mwandu Z, Howard AA, McNairy ML, et al. Evaluation of loss-to-follow-up and post-operative adverse events in a voluntary medical male circumcision program in Nyanza Province, Kenya. Journal of acquired immune deficiency syndromes (1999). 2015.

6. Lebina L, Taruberekera N, Milovanovic M, Hatzold K, Mhazo M, Nhlapo C, et al. Piloting PrePex for Adult and Adolescent Male Circumcision in South Africa—Pain Is an Issue. PLoS one. 2015; 10(9): e0138755. Epub 2015/09/26. https://doi.org/10.1371/journal.pone.0138755 PMID: 26405786.

7. Phill R, Abdool-Karim Q, Ngesa O. Low adverse event rates following voluntary medical male circumcision in a high HIV disease burden public sector prevention programme in South Africa. Journal of the International AIDS Society. 2014; 17(1).

8. Kigozi G, Musoke R, Kihoma N, Kiwanuka N, Makumbi F, Nalugoda F, et al. Safety of medical male circumcision in human immunodeficiency virus-infected men in Rakai, Uganda. Urology. 2014; 83(2):234–7. Epub 2013/11/30. https://doi.org/10.1016/j.urology.2013.08.036 PMID: 24286598.

9. Feldblum PJ, Odoyo-June E, Obiero W, Bailey RC, Combes S, Hart C, et al. Safety, effectiveness and acceptability of the PrePex device for adult male circumcision in Kenya. PLoS one. 2014; 9(5):e95357. Epub 2014/05/03. https://doi.org/10.1371/journal.pone.0095357 PMID: 24788898.

10. Ashengo TA, Grund J, Mhlanga M, Hlophë T, Mirira M, Bock N, et al. Feasibility and validity of telephone triage for adverse events during a voluntary medical male circumcision campaign in Swaziland. BMC Public Health. 2014; 14:858. Epub 2014/08/20. https://doi.org/10.1186/1471-2458-14-858 PMID: 25134856.

11. Duffy K, Gałukande M, Wooding N, Dea M, Coutinho A. Reach and cost-effectiveness of the PrePex device for safe male circumcision in Uganda. PLoS one. 2013; 8(5):e63134. https://doi.org/10.1371/journal.pone.0063134 PMID: 23717402.

12. World Health Organization. WHO Progress Brief: Voluntary Medical Male Circumcision for HIV Prevention In 14 Priority Countries in East And Southern Africa2015 March 1, 2016. http://apps.who.int/iris/bitstream/10665/179933/1/WHO_HIV_2015.21_eng.pdf?ua=1&ua=1.

13. WHO U. Joint Strategic Action Framework to Accelerate the Scale-Up of Voluntary Medical Male Circumcision for HIV Prevention in Eastern and Southern Africa (2012–2016). Geneva: UNAIDS. 2011.
14. Njeuhmeli E, Forsythe S, Reed J, Opuni M, Bollinger L, Heard N, et al. Voluntary medical male circumcision: modeling the impact and cost of expanding male circumcision for HIV prevention in eastern and southern Africa. PLoS medicine. 2011; 8(11):e1001132. https://doi.org/10.1371/journal.pmed.1001132 PMID: 22140367

15. World Health Organization. WHO Technical Advisory Group on Innovations in Male Circumcision: Evaluation of Two Adult Devices. Geneva, Switzerland: WHO, 2013.

16. Musiige AM, Ashengo TA, Stolarsky G, Dialwa RT, Manda R, Ntsuape CO, et al. Participant experiences and views of odor and PrePex device removal pain in a VMMC pilot study in Botswana. Journal of acquired immune deficiency syndromes (1999). 2016; 72(Suppl 1):S73.

17. Bitega JP, Ngeruka ML, Hategakemiana T, Asiimwe A, Binagwaho A. Safety and efficacy of the PrePex device for rapid scale-up of male circumcision for HIV prevention in resource-limited settings. Journal of acquired immune deficiency syndromes (1999). 2011; 58(5):e127–34. Epub 2011/09/13. https://doi.org/10.1097/QAI.0b013e31823546e5 PMID: 21909302.

18. Kigozi G, Moke R, Watya S, Kighoma N, Nakafeero M, et al. The safety and acceptance of the PrePex device for non-surgical adult male circumcision in Rakai, Uganda. A non-randomized observational study. PloS one. 2014; 9(8):e100008. Epub 2014/08/22. https://doi.org/10.1371/journal.pone.0100008 PMID: 25144194.

19. Mutabazi V, Kaplan SA, Rwamasesrabri E, Bitega JP, Ngeruka ML, Savio F, et al. One-arm, arm, open-label, prospective, cohort field study to assess the safety and efficacy of the PrePex device for scale-up of non-surgical circumcision when performed by nurses in resource-limited settings for HIV prevention. Journal of acquired immune deficiency syndromes (1999). 2013; 63(3):315–22. Epub 2013/03/08. https://doi.org/10.1097/QAI.0b013e3182354641 PMID: 23466648.

20. Galukande M, Duffy K, Bitega JP, Rackara S, Bbaale DS, Nakaggwa F, et al. Barriers and facilitators to the uptake of voluntary medical male circumcision among adolescent boys in KwaZulu-Natal, South Africa. African journal of AIDS research: AJAR. 2014; 13(2):179–87. Epub 2014/09/02. https://doi.org/10.2989/16085906.2014.943253 PMID: 25174635.

21. Obiero W, Young MR, Bailey RC. The PrePex device is unlikely to achieve cost-savings compared to the forceps-guided method in male circumcision programs in sub-Saharan Africa. PloS one. 2013; 8(1):e53380. https://doi.org/10.1371/journal.pone.0053380 PMID: 23349708.

22. Tshimanga M, Mangwiro T, Mugurungi O, Xaba S, Munwira M, Kasprzyk D, et al. A Phase II Randomized Controlled Trial Comparing Safety, Procedure Time, and Cost of the PrePex™ Device to Forceps Guided Surgical Circumcision in Zimbabwe. PloS one. 2016; 11(5):e0156220. https://doi.org/10.1371/journal.pone.0156220 PMID: 27227679.

23. Mutabazi V, Bitega JP, Muyenzi Ngeruka L, Nyemazi JP, Dain M, Kaplan SA, et al. Cost Analysis of Adult Male Circumcision with the PrePex Device versus Surgery in Rwanda. Urol Nurs. 2014; 34(6):303–11. Epub 2014/05/07. PMID: 24796170.

24. Kim HY, Lebina L, Milovanovic M, Taruberekera N, Dowdy DW, Martinson NA. Evaluating the cost of adult voluntary medical male circumcision in a mixed (surgical and PrePex) site compared to a hypothetical PrePex-only site in South Africa. Glob Health Action. 2015; 8:29116. Epub 2015/12/19. https://doi.org/10.3402/gha.v8.29116 PMID: 26679407.

25. Galukande M, Duffy K, Bitega JP, Wooding N. Skills training of health workers in the use of a non surgical device (PrePex) for adult Safe Male Circumcision. PloS one. 2014; 9(8):e104893. Epub 2014/08/15. https://doi.org/10.1371/journal.pone.0104893 PMID: 25118716.

26. Mutabazi V, Bitega JP, Ngeruka LM, Hategakemiana T, Kaplan SA, Karemwa C, et al. Non-surgical adult male circumcision using the PrePex device: task-shifting from physicians to nurses. Afr J Reprod Health. 2014; 18(1):61–70. Epub 2014/05/07. PMID: 24796170.

27. Mahajan AP, Sayles JN, Patel VA, Remien RH, Ortiz D, Szekeress G, et al. Stigma in the HIV/AIDS epidemic: a review of the literature and recommendations for the way forward. AIDS (London, England). 2008; 22(Suppl 2):S67.

28. Lissouba P, Taljaard D, Rech D, Doyle S, Shabangu D, Nhlapo C, et al. A model for the roll-out of comprehensive adult male circumcision services in African low-income settings of high HIV incidence: the ANRS 12126 Bophelo Pele Project. PLoS medicine. 2010; 7(7):e1000309. https://doi.org/10.1371/journal.pmed.1000309 PMID: 20652013.

29. George G, Strauss M, Chirawu P, Rhodes B, Frohlich J, Montague C, et al. Barriers and facilitators to the uptake of voluntary medical male circumcision (VMMC) among adolescent boys in KwaZulu-Natal, South Africa. African journal of AIDS research: AJAR. 2014; 13(2):179–87. Epub 2014/09/02. https://doi.org/10.2989/16085906.2014.943253 PMID: 25174635.

30. Skolnik L, Tsiu S, Ashengo TA, Kikaya V, Lukobo-Durrell BC, Kripke KE, et al. Could Circumcision of HIV-Positive Males Benefit Voluntary Male Medical Circumcision Programs in Africa? Mathematical
32. Westercamp N, Bailey R. Acceptability of male circumcision for prevention of HIV/AIDS in sub-Saharan Africa: a review. AIDS and Behavior. 2007; 11(3):341–55. https://doi.org/10.1007/s10461-006-9169-4 PMID: 17053855

33. Morris BJ, Gray RH, Castellsague X, Bosch FX, Halperin DT, Waskett JH, et al. The strong protective effect of circumcision against cancer of the penis. Advances in urology. 2011; 2011.

34. Larke NL, Thomas SL, dos Santos Silva I, Weiss HA. Male circumcision and penile cancer: a systematic review and meta-analysis. Cancer causes & control. 2011; 22(8):1097–110.

35. Tobian AA, Kacker S, Quinn TC. Male circumcision: a globally relevant but under-utilized method for the prevention of HIV and other sexually transmitted infections. Annual review of medicine. 2014; 65:293–306. https://doi.org/10.1146/annurev-med-092412-090539 PMID: 24111891

36. Albero G, Castellsague X, Giuliano AR, Bosch FX. Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sexually transmitted diseases. 2012; 39(2):104–13. PMID: 22249298

37. Serwadda D, Wawer MJ, Makumbi F, Kong X, Kigozi G, Gravitt P, et al. Circumcision of HIV-infected men: effects on high-risk human papillomavirus infections in a randomized trial in Rakai, Uganda. The Journal of infectious diseases. 2010; 201(10):1463–9. Epub 2010/04/08. https://doi.org/10.1086/652185 PMID: 20370481.

38. Mahomed M, Cummings B, Come J, Debora B, Ferreira T, Nhambi L, et al. HIV Is the Primary Exclusion Criterion in a PrePex™ Male Circumcision Device Introductory Study in Mozambique. AIDS research and human retroviruses. 2014; 30(S1):A198–A.

39. Kigozi G, Gray RH, Wawer MJ, Serwadda D, Makumbi F, Watya S, et al. The safety of adult male circumcision in HIV-infected and uninfected men in Rakai, Uganda. PLoS medicine. 2008; 5(6):e116. Epub 2008/06/06. https://doi.org/10.1371/journal.pmed.0050116 PMID: 18532873.

40. Godfrey K, Richard M, Nehemiah K, Stepehn W, Fred N, et al. Male Circumcision Wound Healing in HIV-negative and HIV-positive men in Rakai, Uganda. BJU international. 2013. Epub 2013/09/24. https://doi.org/10.1111/bju.12406 PMID: 24053645.

41. Rogers JH, Odoyo-June E, Jaoko W, Bailey RC. Time to complete wound healing in HIV-positive and HIV-negative men following medical male circumcision in Kisumu, Kenya: a prospective cohort study. PloS one. 2013; 8(4):e61725. Epub 2013/04/25. https://doi.org/10.1371/journal.pone.0061725 PMID: 23613918.

42. Ministry of Health and Child Care Zimbabwe. Accelerated Strategic and Operational Plan 2014–2018: Voluntary Medical Male Circumcision. Harare, Zimbabwe: 2014.

43. World Health Organization. A framework for voluntary medical male circumcision: effective HIV prevention and a gateway to improved adolescent boys’ & men’s health in Eastern and Southern Africa by 20212016 [cited 2017 July 20]. http://apps.who.int/iris/handle/10665/246234.

44. Njuuhmeli E, Hatzold K, Gold E, Mahler H, Kripke K, Seifert-Ahanda K, et al. Lessons Learned From Scale-Up of Voluntary Medical Male Circumcision Focusing on Adolescents: Benefits, Challenges, and Potential Opportunities for Linkages With Adolescent HIV, Sexual, and Reproductive Health Services. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2014; 66:S193–S9. https://doi.org/10.1097/QAI.0000000000000179 PMID: 24918595

45. Government of Zimbabwe. District Health Information Software 2 (DHIS2). In: Zimbabwe Go, editor. DHIS2 ed. Harare: Ministry of Health and Child Care; 2017.

46. Moyo S, Mhloyi M, Chevo T, Rusinga O. Men’s attitudes: A hindrance to the demand for voluntary medical male circumcision—A qualitative study in rural Mhondoro-Ngezi, Zimbabwe. Global public health. 2015;(ahead-of-print):1–13.

47. Hatzold K, Movhu W, Jasai P, Chatora K, Cowan FM, Taruberekera N, et al. Barriers and motivators to voluntary medical male circumcision uptake among different age groups of men in Zimbabwe: results from a mixed methods study. PloS one. 2014; 9(5):e85051. https://doi.org/10.1371/journal.pone.0085051 PMID: 24802746

48. Innocent C, Maxwell M, Augustine N. Correlates of Uptake of Voluntary Medical Male Circumcision among Young Adults in Zimbabwe. International Journal of Health Sciences and Research (IJHSR). 2016; 6(9):330–43.

49. Chiringa IO, Ramathuba DU, Mashau NS. Factors contributing to the low uptake of medical male circumcision in Mutare Rural District, Zimbabwe. African Journal of Primary Health Care and Family Medicine. 2016; 8(2):1–6.

50. Zimbabwe Ministry of Health and Child Care, editor National Overview. VMMC Review and Planning Meeting; 2016; Kadoma, Zimbabwe.
51. World Health Organization. WHO Technical Advisory Group on Innovations in Male Circumcision: Evaluation of two adult devices: Meeting report. Geneva, Switzerland: WHO, January, 2013 8/10/2015. Report No.

52. Byabagamb J, Kigonya A, Lawino A, Ssensamba JT, Twinomugisha A, Karamagi-Nkolo E, et al. A Guide to Improving the Quality of Safe Male Circumcision in Uganda2015 [cited 2016 August 12]. https://www.usaidassist.org/sites/assist/files/uganda_guide_to_improving_the_quality_of_smc_ad_feb2015_ada.pdf.

53. Zimbabwe Ministry of Health and Child Care. Accelerated Strategic and Operational Plan 2014–2018. Harare- Zimbabwe: 2014.

54. Medical Research Council of Zimbabwe. TR025 PrePex MC Classification of Adverse Events and Device Hazards. Revision: 19th June 2012.

55. WHO/UNAIDS. Framework for Clinical Evaluation of Devices for Adult Male Circumcision. Geneva: 2010.

56. Stata Corp LP. Stata Statistical Software Release 12: Stata Press Publication; 2011.

57. Tshimanga M, Gwinji G, Mugurungi O. Evaluation of Safety and Efficacy of PrePex Device for Male Circumcision in Zimbabwe: Phase I: Device Safety Trial Report. Harare, Zimbabwe: Ministry of Health and Child Welfare, 2013.

58. Tshimanga M, Mangwiro T, Xaba S, Chatikobo P, Gundidza P. Evaluation of Safety and Efficacy of Pre-Pex Device for Male Circumcision in Zimbabwe. Phase 3: Cohort Field Study on Safety and Efficacy of the PrePex Circumcision Device when Performed by Nurses. Harare, Zimbabwe: Ministry of Health and Child Welfare, 2013.

59. Bochner A, C F, B M, M H, V M, A S, et al. Adverse event profile of a mature voluntary medical male circumcision progra mme performing PrePex and surgical procedures in Zimbabwe. Journal of the International AIDS Society. 2017;(20:21394). Epub 21 February 2017.

60. Tshimanga M, Mangwiro T, Sinokuthemba X, Chatikobo P, Gundidza P. A Randomized Controlled Trial Comparing the PrePex™ Device to Forceps Guided Surgical Circumcision for Rapid Scale-Up of Male Circumcision in Zimbabwe. Phase II: Randomized Trial Report. Harare, Zimbabwe: Ministry of Health and Child Welfare, 2013.

61. Sokal DC, Li PS, Zulu R, Awori QD, Combes SL, Simba RO, et al. Randomized controlled trial of the shang ring versus conventional surgical techniques for adult male circumcision: safety and acceptability. Journal of acquired immune deficiency syndromes (1999). 2014; 65(4):447–55. Epub 2014/03/04. https://doi.org/10.1097/qai.0000000000000615 PMID: 24583615.

62. Herman-Rloff A, Bailey RC, Agot K. Factors associated with the safety of voluntary medical male circumcision in Nyanza province, Kenya. Bulletin of the World Health Organization. 2012; 90(10):773–81. Epub 2012/10/31. https://doi.org/10.2471/BLT.12.106112 PMID: 23109745.

63. Marongwe P. Routine implementation of ZAZIC VMMC program. In: Feldacker C, editor. Key VMMC follow-up visit details from ZAZIC VMMC Program Officer ed. Harare2016.

64. Baggaley R, Dalal S, Johnson C, Macdonald V, Mameltzis I, Rodolph M, et al. Beyond the 90-90-90: refocusing HIV prevention as part of the global HIV response. Journal of the International AIDS Society. 2016; 19(1).

65. World Health Organization. Guideline on the use of devices for adult male circumcision for HIV prevention2013 [cited 2017 March 2]. http://apps.who.int/iris/bitstream/10665/93178/1/9789241506267_eng.pdf?ua=1.

66. Kigozi G, Museke R, Kighoma N, Watya S, Serwadda D, Nalugoda F, et al. Male circumcision wound healing in human immunodeficiency virus (HIV)-negative and HIV-positive men in Rakai, Uganda. BJU international. 2014; 113(1):127–32. https://doi.org/10.1111/bju.12406 PMID: 24053645.

67. Ministry of Health and Child Care Z. Zimbabwe Population-Based HIV Impact Assessment (Zimphia) 2015–2016: Summary Sheet: Preliminary Findings2016 8/28/2017 [cited 2017 August 28]. http://phia.icap.columbia.edu/wp-content/uploads/2016/11/ZIMBABWE-Factsheet_FIN_.pdf.

68. Odoyo-June E, Rogers JH, Jaoko W, Bailey RC. Changes in plasma viral load and penile viral shedding after circumcision among HIV-positive men in Kisumu, Kenya. Journal of acquired immune deficiency syndromes (1999). 2013. Epub 2013/08/13. https://doi.org/10.1097/QAI.0b013e3182a7ef05 PMID: 23933768.

69. Wawer MJ, Makumbi F, Kigozi G, Serwadda D, Watya S, Nalugoda F, et al. Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial. Lancet. 2009; 374(9685):229–37. Epub 2009/07/21. https://doi.org/10.1016/S0140-6736(09)60998-3 PMID: 19616720.
70. Weiss HA, Hankins CA, Dickson K. Male circumcision and risk of HIV infection in women: a systematic review and meta-analysis. The Lancet infectious diseases. 2009; 9(11):669–77. Epub 2009/10/24. https://doi.org/10.1016/S1473-3099(09)70235-X PMID: 19850225.

71. Moses S, Bailey RC, Ronald AR. Male circumcision: assessment of health benefits and risks. Sexually transmitted infections. 1998; 74(5):368–73. PMID: 10195035

72. Feldblum PJ, Odoyo-June E, Bailey RC, Lai JJ, Weiner D, Combes S, et al. Factors associated with delayed healing in a study of the PrePex device for adult male circumcision in Kenya. Journal of acquired immune deficiency syndromes (1999). 2016; 72(Suppl 1):S24.

73. Kelly R, Kiwanuka N, Wawer MJ, Serwadda D, Sewankambo NK, Wabwire-Mangen F, et al. Age of male circumcision and risk of prevalent HIV infection in rural Uganda. Aids. 1999; 13(3):399–405. PMID: 10199231

74. Larke N, Thomas SL, Dos Santos Silva I, Weiss HA. Male circumcision and human papillomavirus infection in men: a systematic review and meta-analysis. The Journal of infectious diseases. 2011; 204(9):1375–90. Epub 2011/10/04. https://doi.org/10.1093/infdis/jir523 PMID: 21965090.

75. Auvert B, Sobngwi-Tambekou J, Cutler E, Nieuwoudt M, Lissouba P, Puren A, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. The Journal of infectious diseases. 2009; 199(1):14–9. Epub 2008/12/18. https://doi.org/10.1086/595566 PMID: 19086814.

76. Population Services International CoSoE, Central and Southern Africa (COSEC SA), U.S. Centers for Disease Control and Prevention. Adverse Event Action Guide for Voluntary Medical Male Circumcision by Surgery or Device. 2016.